Literature DB >> 367465

Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium.

H J Weiss, V T Turitto.   

Abstract

Prostaglandin I2 (prostacyclin, PGI2), a substance synthesized in the wall of blood vessels, has been previously shown to inhibit the aggregation of platelets in stirred platelet-rich plasma. We used a method in which segments of deendothelialized rabbit aorta are perfused at arterial shear rates with human blood and found that both platelet adhesion and thrombus formation on subendothelium was inhibited in blood containing 10 nM PGI2. PGI2 appears to reduce adhesion by inhibiting platelet spreading. These findings suggest that PGI2 could regulate the deposition of platelets on vascular surfaces.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 367465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Endothelial cell function in diabetic microangiopathy.

Authors:  M Porta; M La Selva; P Molinatti; G M Molinatti
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

Review 2.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

3.  Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention.

Authors:  L A Harker
Journal:  West J Med       Date:  1981-03

4.  Mechanisms of platelet aggregation by viridans group streptococci.

Authors:  P M Sullam; F H Valone; J Mills
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

Review 5.  Eicosanoid storm in infection and inflammation.

Authors:  Edward A Dennis; Paul C Norris
Journal:  Nat Rev Immunol       Date:  2015-07-03       Impact factor: 53.106

6.  Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

Authors:  A H Gershlick; D Spriggins; S W Davies; Y D Syndercombe Court; J Timmins; A D Timmis; M T Rothman; C Layton; R Balcon
Journal:  Br Heart J       Date:  1994-01

7.  Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta.

Authors:  D L DeWitt; J S Day; W K Sonnenburg; W L Smith
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

Review 8.  Prostaglandin I2 (prostacyclin).

Authors:  J G Kelton; M A Blajchman
Journal:  Can Med Assoc J       Date:  1980-01-26       Impact factor: 8.262

9.  Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets.

Authors:  T Fujimoto; S Ohara; J Hawiger
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

10.  Cyclic AMP does not inhibit collagen-induced platelet signal transduction.

Authors:  J B Smith; C Dangelmaier; M A Selak; B Ashby; J Daniel
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.